Literature DB >> 34301779

Production and Supply of α-Particle-Emitting Radionuclides for Targeted α-Therapy.

Valery Radchenko1,2, Alfred Morgenstern3, Amir R Jalilian4, Caterina F Ramogida5,6, Cathy Cutler7, Charlotte Duchemin8,9, Cornelia Hoehr5, Ferrid Haddad10, Frank Bruchertseifer3, Haavar Gausemel11, Hua Yang5, Joao Alberto Osso4, Kohshin Washiyama12, Kenneth Czerwinski13, Kirsten Leufgen14, Marek Pruszyński15,16, Olga Valzdorf17, Patrick Causey18, Paul Schaffer5, Randy Perron19, Samsonov Maxim20, D Scott Wilbur21, Thierry Stora8, Yawen Li21.   

Abstract

Encouraging results from targeted α-therapy have received significant attention from academia and industry. However, the limited availability of suitable radionuclides has hampered widespread translation and application. In the present review, we discuss the most promising candidates for clinical application and the state of the art of their production and supply. In this review, along with 2 forthcoming reviews on chelation and clinical application of α-emitting radionuclides, The Journal of Nuclear Medicine will provide a comprehensive assessment of the field.
© 2021 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  211At; 212Pb/212Bi; 225Ac/213Bi; 227Th/223Ra; production and supply of radionuclides; targeted α-therapy

Mesh：

Year:  2021        PMID： 34301779      PMCID： PMC8612335          DOI： 10.2967/jnumed.120.261016

Source DB:  PubMed          Journal:  J Nucl Med        ISSN： 0161-5505            Impact factor:   11.082


  39 in total

1.  Production of Ac-225 from Th-229 for targeted alpha therapy.

Authors:  C Apostolidis; R Molinet; G Rasmussen; A Morgenstern
Journal:  Anal Chem       Date:  2005-10-01       Impact factor: 6.986

Review 2.  Development of Targeted Alpha Therapy from Bench to Bedside.

Authors:  Alfred Morgenstern; Frank Bruchertseifer
Journal:  J Med Imaging Radiat Sci       Date:  2019-08-09

3.  Preparation of 212Pb-labeled monoclonal antibody using a novel 224Ra-based generator solution.

Authors:  Sara Westrøm; Roman Generalov; Tina B Bønsdorff; Roy H Larsen
Journal:  Nucl Med Biol       Date:  2017-04-26       Impact factor: 2.408

4.  Production of actinium-225 for alpha particle mediated radioimmunotherapy.

Authors:  Rose A Boll; Dairin Malkemus; Saed Mirzadeh
Journal:  Appl Radiat Isot       Date:  2005-01-28       Impact factor: 1.513

5.  Cyclotron production of Ac-225 for targeted alpha therapy.

Authors:  C Apostolidis; R Molinet; J McGinley; K Abbas; J Möllenbeck; A Morgenstern
Journal:  Appl Radiat Isot       Date:  2005-03       Impact factor: 1.513

6.  Alpha emitter radium-223 and survival in metastatic prostate cancer.

Authors:  C Parker; S Nilsson; D Heinrich; S I Helle; J M O'Sullivan; S D Fosså; A Chodacki; P Wiechno; J Logue; M Seke; A Widmark; D C Johannessen; P Hoskin; D Bottomley; N D James; A Solberg; I Syndikus; J Kliment; S Wedel; S Boehmer; M Dall'Oglio; L Franzén; R Coleman; N J Vogelzang; C G O'Bryan-Tear; K Staudacher; J Garcia-Vargas; M Shan; Ø S Bruland; O Sartor
Journal:  N Engl J Med       Date:  2013-07-18       Impact factor: 91.245

7.  The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer.

Authors:  Daniel Heinrich; Jasmin Bektic; Andries M Bergman; Orazio Caffo; Richard Cathomas; Kim N Chi; Gedske Daugaard; Daniel Keizman; Jon Kindblom; Gero Kramer; David Olmos; Aurelius Omlin; Srikala S Sridhar; Marcello Tucci; Inge van Oort; Sten Nilsson
Journal:  Clin Genitourin Cancer       Date:  2017-09-06       Impact factor: 2.872

8.  Automated astatination of biomolecules--a stepping stone towards multicenter clinical trials.

Authors:  Emma Aneheim; Per Albertsson; Tom Bäck; Holger Jensen; Stig Palm; Sture Lindegren
Journal:  Sci Rep       Date:  2015-07-14       Impact factor: 4.379

9.  Simultaneous Separation of Actinium and Radium Isotopes from a Proton Irradiated Thorium Matrix.

Authors:  Tara Mastren; Valery Radchenko; Allison Owens; Roy Copping; Rose Boll; Justin R Griswold; Saed Mirzadeh; Lance E Wyant; Mark Brugh; Jonathan W Engle; Francois M Nortier; Eva R Birnbaum; Kevin D John; Michael E Fassbender
Journal:  Sci Rep       Date:  2017-08-15       Impact factor: 4.379

Review 10.  Development of 225Ac Radiopharmaceuticals: TRIUMF Perspectives and Experiences.

Authors:  Andrew Kyle Henderson Robertson; Caterina Fortunata Ramogida; Paul Schaffer; Valery Radchenko
Journal:  Curr Radiopharm       Date:  2018
View more
  6 in total

1.  Design, synthesis, and preclinical evaluation of a novel bifunctional macrocyclic chelator for theranostics of cancers.

Authors:  Jianfeng Xu; Fei Cai; Zhigang Luo; Wenbin Fan; Juan Dai; Jingjing Cui; Shihong Li; Changran Geng; Qihuang Zheng; Zheng Wang; Xiaobin Tang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-03-26       Impact factor: 10.057

2.  Chelating the Alpha Therapy Radionuclides 225Ac3+ and 213Bi3+ with 18-Membered Macrocyclic Ligands Macrodipa and Py-Macrodipa.

Authors:  Aohan Hu; Victoria Brown; Samantha N MacMillan; Valery Radchenko; Hua Yang; Luke Wharton; Caterina F Ramogida; Justin J Wilson
Journal:  Inorg Chem       Date:  2021-12-29       Impact factor: 5.436

Review 3.  Hydroxypyridinones as a Very Promising Platform for Targeted Diagnostic and Therapeutic Radiopharmaceuticals.

Authors:  Xu Zhou; Linlin Dong; Langtao Shen
Journal:  Molecules       Date:  2021-11-19       Impact factor: 4.411

4.  A Novel Single-Step-Labeled 212Pb-CaCO3 Microparticle for Internal Alpha Therapy: Preparation, Stability, and Preclinical Data from Mice.

Authors:  Ruth Gong Li; Kim Lindland; Tina Bjørnlund Bønsdorff; Sara Westrøm; Roy Hartvig Larsen
Journal:  Materials (Basel)       Date:  2021-11-23       Impact factor: 3.623

5.  Joint EANM, SNMMI and IAEA enabling guide: how to set up a theranostics centre.

Authors:  Ken Herrmann; Luca Giovanella; Andrea Santos; Jonathan Gear; Pinar Ozgen Kiratli; Jens Kurth; Ana M Denis-Bacelar; Roland Hustinx; Marianne Patt; Richard L Wahl; Diana Paez; Francesco Giammarile; Hossein Jadvar; Neeta Pandit-Taskar; Munir Ghesani; Jolanta Kunikowska
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-04-11       Impact factor: 10.057

Review 6.  Radiolabeled PSMA Inhibitors.

Authors:  Oliver C Neels; Klaus Kopka; Christos Liolios; Ali Afshar-Oromieh
Journal:  Cancers (Basel)       Date:  2021-12-13       Impact factor: 6.639
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.